Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new medicine called Risvutatug Rezetecan also known as GSK5764227 in participants worldwide who have advanced gastrointestinal cancers that cannot be surgically removed. This study focuses on participants who have already received prior treatment and aims to assess how well the medicine works, how safe it is, and how the body processes it. It is a Phase 1b2, multicenter, open-label trial sponsored by GlaxoSmithKline. Participants will receive Risvutatug Rezetecan alone or in combination with other treatments. Multiple dosing groups exist, including different doses tailored to colon, rectum, and pancreatic cancer cohorts. The study uses a randomized, parallel design to compare these groups. Treatments are given according to assigned doses, and the trial monitors participants for up to approximately 37 months to assess response and safety. During the study, participants will undergo regular assessments including scans, blood tests, vital signs, and electrocardiograms. Researchers will measure confirmed objective response rates up to about 22 months, and additional outcomes such as progression-free survival, duration of response, adverse events, and changes in clinical and laboratory parameters over about 37 months. Participants are monitored closely for safety and treatment effects throughout their involvement in the trial.